VivoSim Labs (VIVS) Non Operating Investment Income (2022 - 2023)
VivoSim Labs (VIVS) posted quarterly Non Operating Investment Income of $12000.0 for Q2 2023, up 340.0% year-over-year from $2727.3 in Q2 2022, and down 92.11% quarter-over-quarter from $152000.0 in Q1 2023.
VivoSim Labs (VIVS) Non Operating Investment Income (2022 - 2023) Analysis & Trends
VivoSim Labs' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $12000.0 for Q2 2023.
- In Q2 2023, Non Operating Investment Income rose 340.0% year-over-year to $12000.0; the TTM figure through Mar 2024 stood at $12000.0 (down 58.62% YoY), while the FY2026 annual figure was $94000.0, changed N/A from the prior year.
- Non Operating Investment Income for Q2 2023 stood at $12000.0, down from $152000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $152000.0 in Q1 2023, with the low at -$70000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Dec 31, 2022 | -48,000.00 |
| Dec 31, 2022 | -48,000.00 |
| Sep 30, 2022 | -70,000.00 |
| Sep 30, 2022 | -70,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -5,000.00 |